Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Third-Quarter Bead Array Revenues Exceed Expectations Partnerships Add Up

Premium

The Austin, Texas-based company, which derives revenues largely through partnering with other companies that develop applications for its bead arrays, said in a statement that revenues for the quarter ended Sept. 30 would be about $6.2 million, exceeding the $6.1 million offered by an analysts’ consensus estimate.

The company, which plans to report its results after the market closes on Friday, had been expected to lose between 16 cents and 19 cents per share in the third quarter, according to a survey of five analysts by Thomson Financial/First Call. Their consensus forecast was a loss of 18 cents.

Luminex manufactures LabMap technology, in which molecular probes can attach to plastic beads. The company has amassed over 29 development and revenue-sharing agreements so far.

— MMJ

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.